



EXPRESS MAIL NO. EV348173184US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wylie Walker Vale, Jr. et al.
Application No. : 09/919,473
Filed : July 31, 2001
For : UROCORTIN PROTEINS AND USES THEREOF
Examiner : Dr. Olga Chernyshev
Art Unit : 1646
Docket No. : 690068,578
Date : February 12 2004

RECEIVED

FEB 24 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

02/18/2004 NROCHA1 00000007 09919473

01 FC:1806

180.00 OP

A fee of \$180 is submitted in accordance with 37 C.F.R. § 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Karl R. Hermanns
Registration No. 33,507

KRH:ljt
Enclosures:
Form PTO-1449
Cited References (11)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

\455788

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
690068.578APPLICATION NO.
09/919,473

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Wylie Walker Vale, Jr. et al.,

FILING DATE

July 31, 2001

GROUP ART UNIT

1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA		2002/0082409	06/27/02	Hsu	536	23.5	
AB							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AC	WO 97/00063	01/03/97	WIPO	
	AD	WO 02/34934	05/02/02	WIPO	
	AE				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Hsu and Hsueh, "Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor," <i>Nature Medicine</i> 7: 605-611, May 2001.
AG	Lewis, K. et al., "Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor," <i>Proc. Natl. Acad. Sci. USA</i> 98(13): 7570-7575, June 19, 2001.
AH	Reyes, T.M. et al., "Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors," <i>Proc. Natl. Acad. Sci. USA</i> 98(5): 2843-2848, February 27, 2001.
AI	GenBank Database, Accession No. AC005903, January 9, 2003.
AJ	GenBank Database, Accession No. AF331517, March 6, 2001.
AK	GenBank Database, Accession No. BE622276, October 20, 2000.
AL	Hsu, S.Y. et al., "Stresscopins and Their Uses," U.S. Provisional Patent Application No. 60/244,128, filed October 26, 2000.
AM	Hsu, S.Y. et al., "Stresscopins and Their Uses," U.S. Provisional Patent Application No. 60/276,615, filed March 15, 2001.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).